Wells Fargo’s PDL BioPharma, Inc. PDLI Stock Holding History

Wells Fargo’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-389,952	Closed	-$1.23M	–	7468
2020 Q3	$1.23M	Buy	389,952 +62,173	+19%	+$199K	﹤0.01%	3696
2020 Q2	$953K	Buy	327,779 +39,287	+14%	+$124K	﹤0.01%	3851
2020 Q1	$814K	Sell	288,492 -168,179	-37%	-$542K	﹤0.01%	3680
2019 Q4	$1.48M	Sell	456,671 -236,234	-34%	-$686K	﹤0.01%	3583
2019 Q3	$1.5M	Sell	692,905 -29,691	-4%	-$79.4K	﹤0.01%	3560
2019 Q2	$2.27M	Buy	722,596 +382,397	+112%	+$1.24M	﹤0.01%	3239
2019 Q1	$1.26M	Sell	340,199 -5,387	-2%	-$18.2K	﹤0.01%	3708
2018 Q4	$1M	Buy	345,586 +1,187	+0.3%	+$3.26K	﹤0.01%	3850
2018 Q3	$905K	Buy	344,399 +16,140	+5%	+$39.6K	﹤0.01%	4036
2018 Q2	$768K	Sell	328,259 -21,293	-6%	-$59.5K	﹤0.01%	4174
2018 Q1	$1.03M	Sell	349,552 -43,575	-11%	-$119K	﹤0.01%	3899
2017 Q4	$1.08M	Buy	393,127 +47,070	+14%	+$145K	﹤0.01%	3879
2017 Q3	$1.17M	Buy	346,057 +10,239	+3%	+$28.5K	﹤0.01%	3735
2017 Q2	$829K	Sell	335,818 -270,840	-45%	-$623K	﹤0.01%	3871
2017 Q1	$1.38M	Sell	606,658 -42,760	-7%	-$94.6K	﹤0.01%	3496
2016 Q4	$1.38M	Buy	649,418 +458,825	+241%	+$1.28M	﹤0.01%	3463
2016 Q3	$639K	Sell	190,593 -255,492	-57%	-$811K	﹤0.01%	3810
2016 Q2	$1.4M	Sell	446,085 -250,555	-36%	-$836K	﹤0.01%	3236
2016 Q1	$2.32M	Sell	696,640 -74,106	-10%	-$231K	﹤0.01%	2820
2015 Q4	$2.73M	Sell	770,746 -1,209,648	-61%	-$5.06M	﹤0.01%	2757
2015 Q3	$9.96M	Buy	1,980,394 +55,369	+3%	+$317K	﹤0.01%	1800
2015 Q2	$12.4M	Sell	1,925,025 -523,298	-21%	-$3.51M	﹤0.01%	1737
2015 Q1	$17.2M	Sell	2,448,323 -767,336	-24%	-$5.56M	0.01%	1442
2014 Q4	$24.8M	Sell	3,215,659 -832,793	-21%	-$6.59M	0.01%	1152
2014 Q3	$30.2M	Sell	4,048,452 -50,460	-1%	-$468K	0.01%	1007
2014 Q2	$39.7M	Buy	4,098,912 +1,413,224	+53%	+$12.6M	0.02%	893
2014 Q1	$22.3M	Buy	2,685,688 +2,048,581	+322%	+$17.6M	0.01%	1192
2013 Q4	$5.38M	Buy	637,107 +98,433	+18%	+$830K	﹤0.01%	2210
2013 Q3	$4.29M	Sell	538,674 -47,498	-8%	-$382K	﹤0.01%	2307
2013 Q2	$4.52M	Buy	+586,172	New	+$4.57M	﹤0.01%	2205

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Wells Fargo's PDLI Position: Q4 2020 in Review

Wells Fargo sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 389,952 shares — an estimated $1.23M sold.

Wells Fargo first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $39.7M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Wells Fargo reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Wells Fargo sold 389,952 PDL BioPharma, Inc. shares in Q4 2020, an estimated $1.23M.
Wells Fargo first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
Wells Fargo's PDL BioPharma, Inc. position peaked at $39.7M in Q2 2014.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Wells Fargo's 13F filing for Q4 2020, filed 9 Feb 2021.